SARS-CoV-2 Nucleocapsid Antibody (4D0J7) [CoraFluor™ 1]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-05764CL1

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

SARS-CoV-2

Applications

ELISA, ELISA Capture (Matched Antibody Pair), Surface Plasmon Resonance

Label

CoraFluor 1

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # 4D0J7

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all SARS-CoV-2 Nucleocapsid Antibodies »

Product Specifications

Immunogen

HK293 derived SARS-COV-2 Nucleocapsid Ser2-Ala419 Accession #YP_009724397.2

Reactivity Notes

No cross-reactivity in ELISA with MERS-CoV Nucleoprotein protein and HCoV-229E Nucleoprotein protein

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Description

CoraFluor(TM) 1 is a high performance terbium-based TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) or TRF (Time-Resolved Fluorescence) donor for high throughput assay development. CoraFluor(IM) 1 absorbs UV light at approximately 340 nm, and emits at approximately 490 nm, 545 nm, 585 nm and 620 nm. It is compatible with common acceptor dyes that absorb at the emission wavelengths of CoraFluor(TM) 1. CoraFluor(TM) 1 can be used for the development of robust and scalable TR-FRET binding assays such as target engagement, ternary complex, protein-protein interaction and protein quantification assays.

Applications for SARS-CoV-2 Nucleocapsid Antibody (4D0J7) [CoraFluor™ 1]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

ELISA Capture (Matched Antibody Pair)

Optimal dilutions of this antibody should be experimentally determined.

Surface Plasmon Resonance

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Affinity purified

Formulation

PBS

Preservative

No Preservative

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark. Do not freeze.

Background: SARS-CoV-2 Nucleocapsid

The SARS-CoV-2 Nucleocapsid protein is one of the four major structural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1,2). The nucleocapsid protein is an RNA-binding protein that is essential for viral assembly into a ribonucleoprotein complex and also functions in viral budding (2,3). More specifically, after viral replication and RNA synthesis, the viral genomes that are encapsulated by the nucleocapsid protein will bud into the membrane and help with mature virus formation (2). The nucleocapsid protein is synthesized as 419 amino acids (aa) in length with a theoretical molecular weight of 45.6 kDa (4). Structurally, the nucleocapsid protein contains an RNA-binding domain (N1b), a dimerization domain (N2b), and a few shorter regions (N1a, N2a, and spacer B/N3) (3). It is the N1b domain that is suggested to be involved in RNA binding (3). The nucleocapsid N1b domain contains a beta-hairpin, a loop region, and a beta-sheet core, giving it a right-handed shape (3). Conversely, the N2b domain functions in dimerization which promotes assembly into a helical filament where the dimer interface is made of two beta-strands and an alpha-helix portion (3). Inhibition of nucleocapsid assembly may be a potential target for treating COVID-19 infection.

Following SARS-CoV-2 infection, B cells and T cells display an immune response against nucleocapsid protein and nucleocapsid-specific neutralizing antibodies are produced (5). Interestingly, a study of patients who have recovered from COVID-19 revealed that there were no neutralizing antibodies against nucleocapsid protein present; however, a high presence against neutralizing spike RBD antibodies were detected (5).

References

1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658

2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.

3. Zhu, G., Zhu, C., Zhu, Y., & Sun, F. (2020). Minireview of progress in the structural study of SARS-CoV-2 proteins. Current Research in Microbial Sciences. https://doi.org/10.1016/j.crmicr.2020.06.003

4. Uniprot (P0DTC9)

5. Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020). Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.01949

Alternate Names

2019-nCoV N Protein, 2019-nCoV Nucleocapsid Protein, COVID-19 N protein, COVID-19 nucleocapsid protein, Human coronavirus Nucleoprotein, nucleocapsid phosphoprotein, Nucleocapsid protein, Nucleoprotein, ORF9; structural protein, SARS-CoV-2, SARS-CoV-2 Nucleocapsid protein, SARS-CoV-2 N protein, SARSCoV2 Nucleoprotein, Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein

Gene Symbol

N

Additional SARS-CoV-2 Nucleocapsid Products

Product Documents for SARS-CoV-2 Nucleocapsid Antibody (4D0J7) [CoraFluor™ 1]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for SARS-CoV-2 Nucleocapsid Antibody (4D0J7) [CoraFluor™ 1]

CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.